PanACEA project

PanACEA project

Kilimanjaro Clinical Research Institute (KCRI) is the secretariat of PanACEA. The overall objectives for the PanACEA program focus on the effective, efficient conduct of the clinical trials and on establishing an enduring framework to benefit future trials of TB drugs.

Only with a consortium of clinical trials and trial sites can these objectives be accomplished at the comprehensive scope required to transform TB drug development and improve TB treatment regimes that have not changed significantly over the past 35 years.

The proposed objectives for PanACEA include the following:

  1. Shorten and simplify TB Therapy.
  2. Establish TB Clinical Trial capacity.
  3. Establish Tools and framework for TB trials.

The PanACEA consists of the three consortia:

  1. REMox.
  3. SQ109.

The consortia will perform the drug development programme in 12 African sites:

  1. Kilimanjaro Clinical Research Institute (KCRI), KCMC, Tanzania.
  2. Aurum Institute for Health Research, South Africa.
  3. Makerere University, Uganda.
  4. Mbeya Medical Research Program, Tanzania.
  5. University of Stellenbosch, South Africa.
  6. University of Cape Town,South Africa.
  7. University of Zambia, Zambia.
  8. University of the Witwaterstand, South Africa.
  9. Bagamoyo IHRDC and Swiss Trop. Inst, Tanzania.
  10. Albert Schweitzer Hospital- Lambarene, Gabon.
  11. South African MRC (Durban), South Africa.
  12. Kenya Medical Research Institute. Kenya.

PanACEA is funded for a period of 5 years. In this period the deliverables will be to have tried moxifloxacin beyond phase III, high dose rifampicin and SQ 109 beyond phase II, have developed the trial sites to be able to perform GCP/GCLP regulatory standard clinical trials in TB drug development and have secured additional funding to build a sustainable programme.

PanACEA sharepoint link